Annual report pursuant to Section 13 and 15(d)

COMMON STOCK

v3.22.0.1
COMMON STOCK
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
COMMON STOCK
13.
COMMON STOCK

 

The Company has authorized 300,000,000 shares of common stock, $0.0001 par value per share, of which 125,230,881 shares were issued and outstanding as of December 31, 2021. The Company had 150,000,000 shares authorized, and 98,852,696 shares were issued and outstanding as of December 31, 2020.

 

On February 11, 2020, the Company consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 7,666,667 shares of its common stock, including 1,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a purchase price of $6.00 per share with gross proceeds to the Company totaling $46,000,000, less estimated issuance costs incurred of approximately $3,147,000.

 

On April 7, 2020, the Company entered into an Open Market Sale Agreement (the “April 2020 Sale Agreement”) with Jefferies pursuant to which Jefferies served as the Company’s sales agent to sell up to $75,000,000 of shares of the Company’s common stock through an “at the market offering”. Sales of common stock under the April 2020 Sale Agreement were made pursuant to an effective registration statement for an aggregate offering of up to $75,000,000. During the year ended December 31, 2021, the Company did not sell any shares of its common stock under the April 2020 Sale Agreement. During the year ended December 31, 2020, the Company sold 10,539,374 shares of its common stock under the April 2020 Sale Agreement for which the Company received gross proceeds of approximately $75,000,000, less issuance costs incurred of approximately $2,250,000 through December 31, 2020. The Company completed sales of the $75,000,000 of shares of the Company’s common stock under the April 2020 Sale Agreement prior to beginning to sell shares under the August 2020 Sale Agreement.

 

On August 7, 2020, the Company entered into the August 2020 Sale Agreement with Jefferies pursuant to which Jefferies is serving as the Company’s sales agent to sell shares of the Company’s common stock through an “at the market offering.” As of August 7, 2020, the company was authorized to sell up to $150,000,000 of shares of the Company’s common stock pursuant to the August 2020 Sale Agreement. During the year ended December 31, 2021, the Company sold 25,391,710 shares of its common stock under the August 2020 Sale Agreement for which the Company received gross proceeds of approximately $60,681,238, less issuance costs incurred of approximately $1,820,437 through December 31, 2021. During the year ended December 31, 2020, the Company sold 15,546,151 shares of its common stock under the August 2020 Sale Agreement for which the Company received gross proceeds of approximately $21,404,000, less issuance costs incurred of approximately $642,000 through December 31, 2020.

 

During the year ended December 31, 2021 and 2020, the Company issued 838,600 and 427,611 shares of common stock upon the exercise of stock options to purchase common stock and the Company received proceeds of approximately $945,000 and $756,000 from these exercises, respectively.

 

During the year ended December 31, 2021, the Company issued 147,875 shares of restricted common stock pursuant to the Milky Way License Agreement. No restricted common shares were issued during the year ended December 31, 2020.

 

No warrants were exercised during the years ended December 31, 2021 and 2020.